Lung Cancer Genomic Testing Market - Global Forecast 2025-2032

The lung cancer genomic testing market is rapidly evolving, equipping healthcare organizations with advanced solutions to drive more targeted, data-driven oncology care. For senior decision-makers, the integration of leading-edge genomic diagnostics is now pivotal for aligning clinical protocols with organizational imperatives and achieving both improved outcomes and operational resilience.

Market Snapshot: Lung Cancer Genomic Testing Market Size & Growth

The global lung cancer genomic testing market continues to expand robustly, with the market size increasing from USD 1.07 billion in 2024 to USD 1.16 billion in 2025, and it is projected to reach USD 2.07 billion by 2032 at a CAGR of 8.56%. Ongoing advancements in next generation sequencing, widespread adoption of companion diagnostics, and growing use of liquid biopsy technologies are fueling this growth. Healthcare organizations are focusing on platforms that deliver high sensitivity, operational scalability, and robust patient-specific genomic insights. Market entrants are leveraging automation and data analytics to drive efficiency and meet the mounting demand in both clinical and research contexts.

Lung Cancer Genomic Testing Market: Scope & Segmentation

This report offers comprehensive analysis and actionable insights into the technology adoption, emerging clinical needs, and operational frameworks shaping the lung cancer genomic testing landscape across multiple dimensions. The segmentation detailed below enables informed decision-making for technology investment, clinical integration, and market expansion:

• Technologies: Fluorescence In Situ Hybridization, Microarray Platforms, Next Generation Sequencing including targeted and whole exome/genome approaches, Real Time Polymerase Chain Reaction, and Sanger Sequencing. These tools extend mutation analysis granularity and support data-driven clinical decisions.
• Test Types: Liquid Biopsy methods, such as Circulating Tumor Cells and Circulating Tumor DNA, support non-invasive diagnostics. Tissue Biopsy approaches, including Fine Needle Aspiration and Tissue Section analysis, are integrated in established clinical workflows.
• Applications: Companion Diagnostics, Predictive Testing, Prognostic Testing, and frameworks for Treatment Monitoring guide therapeutic decisions, enable timely risk assessment, and inform patient management pathways.
• End Users: Academic and Research Institutes, Hospitals and Diagnostic Laboratories, and Pharmaceutical and Biotechnology Companies all lead innovation, validation, and translation of genomic insights to patient care.
• Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific are analyzed in depth, with regional spotlights on innovation drivers, access expansion, and evolving health system strategies.
• Company Coverage: Leading participants such as Illumina, Inc.; Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche AG; QIAGEN N.V.; Guardant Health, Inc.; Myriad Genetics, Inc.; Natera, Inc.; BioMérieux S.A.; NeoGenomics Laboratories, Inc.; and Foundation Medicine, Inc. are featured to illustrate technology diversity and operational capacity.

The growing integration of genomic data into standard care, alongside improved sample processing and rising use in varied practice settings, underscores each segment's relevance for achieving leadership in oncology diagnostics.

Key Takeaways for Senior Decision-Makers

• Comprehensive genomic profiling, especially through next generation sequencing, is supporting more precise and individualized oncology strategies across patient cohorts.
• Collaboration among diagnostics developers, pharmaceutical organizations, and academic research centers accelerates clinical validation, enabling faster adoption of companion diagnostics in practice.
• Adaptive regulatory frameworks are helping healthcare stakeholders adopt new genomic assays quickly while upholding clinical quality benchmarks.
• Diversified diagnostic portfolios, combined with advanced bioinformatics, cloud-based data solutions, and automation, are crucial for driving operational efficiencies and market distinction.
• Expansion of regional diagnostic capacities through public-private partnerships strengthens health system innovation and enhances responsiveness to changing clinical needs.

Tariff Impact on Lung Cancer Genomic Testing Supply Chains

Following post-2025 US-imposed tariffs on imported diagnostic equipment and reagents, supply chains in the lung cancer genomic testing market are undergoing significant adjustments. Laboratories and healthcare organizations are prioritizing domestic manufacturing cooperation and forging long-term supply partnerships to minimize risk and maintain continuity. Production is increasingly being localized to high-demand regions, which shortens delivery times and reduces reliance on complex global logistics networks. These measures empower stakeholders to remain agile and resilient in response to global trade policy shifts.

Methodology & Data Sources

This report’s market intelligence is grounded in interviews with molecular pathologists, clinical oncologists, laboratory executives, and logistics experts. Supplementary insights are derived from peer-reviewed scientific literature, regulatory filings, company financials, and trusted industry repositories, with all projections validated through expert review and robust statistical analysis.

Why This Report Matters for Industry Leadership

• Provides targeted market intelligence and clear analysis to inform strategic plans and pinpoint high-value investment prospects.
• Highlights opportunities for operational advancement and collaborative innovation tailored to specific hospital, regional, or research contexts.
• Prepares leadership teams to navigate complex regulatory landscapes, harness emerging technologies, and address intricate supply chain demands for sustained market advantage.

Conclusion

The lung cancer genomic testing market is progressing through increased clinical integration and sector collaboration. Leaders prioritizing scalable solutions and adaptive operations are strongly positioned to address evolving demands and organizational goals in modern oncology care.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.